Premier Research Names Patrick Melvin as Senior Director, Clinical Trial ... ( PHILADELPHIA Jan. 15 /- Premier R...)

Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management

Date:1/15/2008

PHILADELPHIA, Jan. 15 /PRNewswire/ -- Premier Research Group plc (AIM: PRG), the international pharmaceutical services group, announces the appointment of Patrick Melvin as Senior Director, Clinical Trial Management specializing in oncology-related research. In this position, Mr. Melvin will play a leading role in the operations, strategic planning and corporate development of Premier Research's growing portfolio of oncology business.

Over the past nine years, Mr. Melvin managed hematology/oncology programs ranging from Phase I first-in-man studies through pivotal global Phase III programs. His early phase experience included multiple variations of early phase designs, including PK/PD studies, traditional dose-escalating maximum tolerated dose studies, Simon two-stage studies, and adaptive design studies. The later phase studies included extensive global experience in hematology/oncology clinical research including clinical program and client activities in the United States, Western and Eastern Europe, Latin America, and Asia. His responsibilities incorporated consulting with clients on clinical development plans and protocol design for new hematology/oncology studies. Mr. Melvin began his clinical research career as a CRA at a global clinical research organization and, after five years of serving in various monitoring positions, entered project management specializing in hematology and oncology drug development.

"Mr. Melvin is an exceptional addition to our team," said Krista Armstrong, Ph.D., Vice President, Clinical Trial Management. "As we continue to expand our presence within the oncology market, Mr. Melvin's substantial clinical and management expertise will be beneficial in continuing to establish Premier Research as an industry leader."

About Premier Research

Premier Research is a leading solutions-driven CRO leveraging their commitment to therapeutic focus and scientific expertise to deliver clinical trial services of the
'/>"/>

SOURCE Premier Research Group plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
2. Premier Research Appoints Global Head of Human Resources
3. Premier Research Appoints Melissa Jones as Vice President, International Business Development
4. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
5. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
6. A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations.
7. Association of Clinical Research Organizations (ACRO) Elects New Officers for 2008
8. Biomoda Hires Senior Scientist to Expand Research & Development Effort
9. Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI
10. SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations
11. Researchers use magnetism to target cells to animal arteries

Post Your Comments:

(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,

(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering

(Date:12/2/2009)JERUSALEM, Israel, December 2 Gamida Cell announced today,a feasibility study evaluating the preclinical (animal study) safety and,efficacy of a gene therapy product which combines technology from We

(Date:12/2/2009)QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today annou

[0] Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities [0] Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option [0] Gamida Cell Announces Feasibility Study With Weill Cornell Medical College [0] AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma

...ons is pleased to welcome Richard Duffey, M.D., to...in Mobile, Alabama and also serves patients from P...and Pascagoula communities in Mississippi.,Trusted... LASIK Eye Surgeons directory service and informat...geons.com . What sets the Trusted LASIK Surgeons d...

...tion (OTC: MYMX), will be holding an important con... New York Time to update all shareholders,on the r...Form 10-Q and to,address recent press articles., ...866-591-4361 PIN 815,726 and from Europe at +41-80...Mymetics, primary objective is to develop vaccines...

...aqGS: VARI) introduced its new dual wavelength X-r...les and proteins. The SuperNova(TM) is the,first d...high intensity,micro-source X-ray technology. It i...ata analysis, enabling faster results even for the... diffraction is used to determine the structure of...

Other Biology Technology:Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 2 Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 3 Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 4 Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 5 Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 6 New Dual Wavelength X-ray Diffractometer From Oxford Diffraction, Now a Part of Varian, Inc., Allows Increased Throughput for Challenging Single Crystal Analyses 2

Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers Mymetics Corporation Important Shareholders Information Conference Call New Dual Wavelength X-ray Diffractometer From Oxford Diffraction, Now a Part of Varian, Inc., Allows Increased Throughput for Challenging Single Crystal Analyses

(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin

(Date:12/2/2009)PHILADELPHIA New study results strengthen the evidence that people who smoke cigarettes over a long period of time have an increased risk for developing colorectal cancer, even after adjusting for ot

(Date:12/2/2009)PHILADELPHIA Exposure to secondhand smoke for a prolonged period of time and in high quantity may increase the risk of breast cancer, even in women who never smoked cigarettes themselves. , "The qu

Breaking Biology News(10 mins):Grooving down the helix 2 Grooving down the helix 3 Cigarette smoking increases colorectal cancer risk 2 Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life 2 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 1 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 2 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 3 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 4 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 5 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 6 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 7 Gen Probe to Webcast Two Upcoming Investor Presentations 5888 1 Gen Probe to Webcast Two Upcoming Investor Presentations 5888 2 Patients More Likely to Die While in ICU in U S Than in England 60428 1 Patients More Likely to Die While in ICU in U S Than in England 60428 2

[0] Grooving down the helix [0] Cigarette smoking increases colorectal cancer risk [0] Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life

...ommonwealth University Massey Cancer Center have f...ement of human breast cancer cells toward epiderma...nal of Biological Chemistry, researchers showed th... role in breast cancer progression, stimulates sph...nzymes that forms the potent lipid mediator, sphin...

...ar subtleties of a strain of mice engineered to ag...ion of genetic mutations prompts a cascade of prog... process. , Writing today (July 15, 2005) in the j...sity of Wisconsin-Madison geneticist Tomas A. Prol... normal mice that peel away some of the root secre...

...global health threat. Although more than 3 billion...o fight tuberculosis, the ability of the BCG vacci...ficacy against newly emerging isolates. , In a stu...nt publication of the September 1 issue of the Jou...d colleagues from the Max Planck Institute devise ...

Other Biology News:Elderly mice yield clues to the process of growing old 2 Elderly mice yield clues to the process of growing old 3

VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells Elderly mice yield clues to the process of growing old Agilent Technologies Introduces First Commercial Mouse Microarray for Comparative Genomic Hybridization Research

T7 RNA Polymerase from Invitrogen

T7 RNA polymerase from Chimerx

Hexokinase/ Glucose-6-Phosphate Dehydrogenase from Roche Applied Science

RNase H from Roche Applied Science

Biology Products:

T7 RNA Polymerase from Invitrogen T7 RNA polymerase from Chimerx Hexokinase/ Glucose-6-Phosphate Dehydrogenase from Roche Applied Science RNase H from Roche Applied Science

Premier Research Names Patrick Melvin as Senior Director, Clinical Trial ...( PHILADELPHIA Jan. 15 /- Premier R...)